Galaxy Publication

Theoretical Model of Thiophene and Its Derivatives Interaction with BRCA-1

Lauro FigueroaValverde[1], RosasNexticapa Marcela[2], Magdalena AlvarezRamirez[2], Maria Lopez-Ramos[1], Virginia MateuArmand[2]*, HernandezVazquez Patricia[2]

[1]Pharmacochemistry Research Laboratory, Faculty of BiologicalChemical Sciences, University Autonomous of Campeche; Humberto Lanz Cárdenas s/n, Ex Hacienda Kalá, C.P. 24085, Campeche, Mexico.
[2]Nutrition Laboratory, Faculty of Nutrition, University of Veracruz, Medicos y s/n Odontologos 910210, Unidad del Bosque, Xalapa, Mexico.

*E-mail ✉ lfiguero@uacam.mx

ABSTRACT

Research indicates a growing association between breast cancer and increased mortality rates across the globe. Various risk factors, such as obesity, high-fat diets, lack of physical exercise, alcohol use, oral contraceptive consumption, genetic mutations, and others, contribute to the development of breast cancer. In addition, some studies have pointed to the role of the breast cancer gene 1 (BRCA1) in breast cancer onset. The objective of this study was to investigate how thiophene (1) and its derivatives (2 to 25) interact with BRCA-1, using the 3pxb protein and niraparib as control compounds in a docking simulation. The results showed changes in the interaction of thiophene and its analogs with the 3pxb protein surface when compared to the niraparib drug. In addition, the inhibition constants (Ki) of thiophene-derivative-protein complexes for compounds 11, 13, 16, 18, and 20 showed similar patterns to that of niraparib. These findings suggest that these specific compounds may inhibit the activity of BRCA-1, which could lead to a reduction of breast cancer cell proliferation.

Keywords: BRCA-1, Cancer, Thiophene, Derivatives

Introduction

Breast cancer has become increasingly prevalent in women over the years, leading to a rise in mortality rates globally [1, 2]. A range of risk factors have been identified as contributing to the onset of breast cancer, including demographic, reproductive, hormonal, genetic, and lifestyle factors [3]. Various therapeutic agents are currently used in breast cancer treatment, such as tamoxifen (a drug targeting estrogen receptors) [4], trastuzumab [5], pertuzumab [6], margetuximab [7], lapatinib [8], neratinib/fulvestrant [9], tucatinib [10], everolimus [11], alpelisib [12], capivasertib/fulvestrant [13], and olaparib [14]. However, some of these treatments come with side effects, such as diarrhea, nausea, and neutropenia [15]. To find new therapeutic options, several drugs have been developed, including niraparib (MK-4827), an ADP-ribose polymerase inhibitor that shows effectiveness against tumors with BRCA-1 and BRCA-2 mutations [16]. Additionally, drugs like olaparib and talazoparib have been approved for treating breast cancers harboring BRCA-1 or BRCA-2 mutations [17]. Phase III clinical trials have demonstrated that both olaparib and talazoparib offer significant benefits to breast cancer patients [18]. Other studies have shown that compounds like benzo[a]pyrene and its epoxide diol can influence BRCA-1 expression [19]. Moreover, a carboxamide derivative has demonstrated activity against the MDA-MB-436 breast cancer cell line, which carries the BRCA-1 mutation [20].

In addition, several thiophene derivatives have been synthesized to evaluate their potential anti-cancer effects. One study highlighted a chloro-benzothiophene analog that exhibited biological activity against the MCF-7 breast

cancer cell line [21]. Another study found that a thiophene derivative (4-Methyl-5-(phenyldiazenyl)-2-[((1-(thiophen-2-yl) ethylidene)hydrazineylidene]-thiazol-3(2H)amine) inhibited growth in MCF-7 cancer cells [22]. Further findings showed that a pyrimido-thieno-pyrimidine thiophene derivative reduced the growth of both MCF-7 and A549 cancer cell lines by targeting the epidermal growth factor receptor [23]. In addition, a dioxo-benzo[b]-thiophene derivative was identified as a YAP-TEAD (transcriptional regulators) inhibitor in breast cancer, demonstrating activity in a cancer cell model [24]. Additionally, a thiophene-triazine derivative inhibited MCF-7 cancer cell growth through the PI3K/mTOR (phosphoinositide 3-kinase/mammalian target of rapamycin) pathway [25]. These results suggest that certain thiophene derivatives may hold promise as inhibitors of breast cancer growth, but their specific interactions with molecules involved in cell proliferation in breast cancer remain unclear. Consequently, this study sought to investigate the potential interactions between several thiophene compounds (1) and their analogs (2 to 25) with BRCA-1 (breast cancer gene 1) using a theoretical modeling approach.

Materials and Methods

The chemical structures of thiophene and its derivatives, which were utilized to explore their potential interaction with the BRCA-1 gene surface, are depicted in **Figure 1**.


Figure 1. Chemical structure of thiophene (1) and its derivatives (2-25); 1 = thiophene, 2 = 1-benzothiophene-4-ol, 3 = 1-methylbenzo(b)naphtho(1,2-d)-thiophene, 4 = 2-([(E)-(3,5-Dichloro-2-hydroxyphenyl)methylidene]amino)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carbonitrile, 5 = 2-(1H-imidazol-1-ylmethyl)-4,5-dihydrobenzo(b)thiophene-6-carboxylic acid, 6 = 2-(Chloromethyl)-thiophene, 7 = 2-(tert-butoxy)thiophene, 8 = 2,2,3-trifluoro-2,4,5,6,7,8-hexahydrocyclohepta(b)thiophene, 9 = 2,5-dimethyltetrahydrothiophene, 10 = 3-(2-(Dimethylamino)ethyl)-5-methoxybenzo(b)thiophene, 11 = 3-(2-(dimethylamino)ethyl)benzo(b)thiophene, 12 = 3-(2-(methylamino)ethyl)benzo(b)thiophene, 13 = 3-(2-aminoethyl)-5-methoxybenzo(b)thiophene, 14 = 3-formylthiophene, 15 = 3-methylbenzo(b)naphtho(1,2-d)thiophene, 16 = 3-nitrobenzo(b)thiophene, 17 = 4-methylbenzo(b)naphtho(2,3-d)thiophene, 18 = 5-bromo-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-thiophene, 19 = 6-methylbenzo(b)naphtho(2,1-d)thiophene, 20 = 6-methylbenzo(b)thiophene, 21 = -benzothiophene 1,1-dioxide, 22 = tetrahydro-thiophene-1-oxide, 23 = N-[[4-[(thiophene-2-carbonylamino)carbamoyl]cyclohexyl]methyl]thiophene-2-sulfonamide, 24 = naphtho(2,1-b)thiophene, 25 = 19-thiapentacyclo[14.2.1.05,18.06,11.012,17]nonadeca-1,3,5(18), 6,8,10, 12(17),13,15-nonaene

Ligand-protein complex
The interaction between thiophene and its derivatives with the BRCA-1 gene was assessed by modeling their binding to the 3pxb [26] protein and using niraparib (MK-4827) as a reference in the DockingServer software [27].

Pharmacokinetics parameter
The pharmacokinetic properties of thiophene derivatives (11, 13, 16, 18, and 20) were analyzed through the SwissADME software [28].

Toxicity analysis
The potential toxicity of thiophene derivatives (11, 13, 16, 18, and 20), as well as niraparib, was evaluated by considering various administration routes using the GUSAR program [29].

Results and Discussion

Previous research indicates that several thiophene derivatives have shown potential biological activity against cancer cells [21-25]; however, these findings have often been inconsistent. In light of these varying results, this study focused on exploring how thiophene and its analogs might interact with specific biomolecules related to cancer progression, like BRCA-1, using the 3pxb protein and niraparib in a docking simulation. The outcomes **(Table 1; Figure 2)** revealed that LJH685 engages with a variety of amino acid residues (Leu1679, Ile1680, Arg1699, Ala1700, Leu1701, Lys1702, Leu1705, Gln1779) on the 3pxb protein's surface, which was not observed with thiophene (1) or its other derivatives (2 to 25). This indicates that the binding of thiophene and its analogs to the 3pxb protein depends on the distinct chemical structures of each compound **(Table 1; Figure 2)** and various thermodynamic factors that influence the formation of the thiophene-protein complex.

Table 1. Theoretical interaction of thiophene (1) and its analogs (compounds 2-25) with 3pxb protein surface

Compound	Aminoacid residues
Niraparib	Leu_{1679}; Ile_{1680}; Arg_{1699}; Ala_{1700}; Leu_{1701}; Lys_{1702}; Leu_{1705}; Gln_{1779}
1	Ile_{1680}; Leu_{1701}; Lys_{1702}; Leu_{1705}; Gln_{1779}
2	Glu_{1698}; Arg_{1699}; Val_{1740}; Val_{1741}
3	Glu_{1698}; Arg_{1699}; Ala_{1700}; Asn_{1774}; Met_{1775}; Arg_{1699}; Leu_{1839}
4	Arg_{1699}; Ala_{1700}; Leu_{1701}; Lys_{1702}; Asn_{1774}; Met_{1775}
5	Ser_{1655}; Ala_{1700}; Leu_{1701}; Lys_{1702}; Phe_{1704}; Asn_{1774}; Met_{1775}; Arg_{1835}; Leu_{1839}
6	Arg_{1699}; Phe_{1704}; Asn_{1774}; Met_{1775}; Arg_{1835}; Leu_{1839}
7	Leu_{1701}; Phe_{1704}; Asn_{1774}; Met_{1775}; Arg_{1835}; Leu_{1839}
8	Arg_{1699}; Leu_{1701}; Phe_{1704}; Met_{1775}; Leu_{1839}
9	Phe_{1704}; Asn_{1774}; Met_{1775}; Arg_{1835}; Leu_{1839}
10	Glu_{1698}; Arg_{1699}; Phe_{1704}; Met_{1775}
11	Glu_{1698}; Ala_{1700}; Leu_{1701}
12	Glu_{1698}; Arg_{1699}; Phe_{1704}; Met_{1775}; Leu_{1839}
13	Glu_{1698}; Ala_{1700}; Leu_{1701}
14	Ile_{1680}; Leu_{1701}; Lys_{1702}; Leu_{1705}
15	Glu_{1698}; Arg_{1699}; Ala_{1700}; Met_{1775}; Leu_{1839}
16	Arg_{1699}; Leu_{1701}; Phe_{1704}; Met_{1775}; Leu_{1839}
17	Ala_{1700}; Leu_{1701}; Met_{1775}; Arg_{1835}; Leu_{1839}
18	Glu_{1698}; Arg_{1699}; Ala_{1700}; Val_{1740}; Val_{1741}; Thr_{1773}; Asn_{1774}; Met_{1775}; Arg_{1835}
19	Arg_{1699}; Ala_{1700}; Leu_{1701}; Met_{1775}; Leu_{1839}
20	Arg_{1699}; Leu_{1701}; Phe_{1704}; Asn_{1774}; Met_{1775}; Arg_{1835}; Leu_{1839}
21	Arg_{1699}; Phe_{1704}; Asn_{1774}; Met_{1775}; Leu_{1839}
22	Ile_{1680}; Leu_{1701}; Lys_{1702}; Leu_{1705}

|	
23	Ser$_{1655}$; Glu$_{1698}$; Arg$_{1699}$; Ala$_{1700}$; Leu$_{1701}$; Asn$_{1774}$; Met$_{1775}$
24	Arg$_{1699}$; Leu$_{1701}$; Phe$_{1704}$; Met$_{1775}$; Leu$_{1839}$
25	Glu$_{1698}$; Arg$_{1699}$; Leu$_{1701}$; Met$_{1775}$; Leu$_{1839}$

Figure 2. Binding of thiophene analogs (11, 13, 16, 18, and 20) with the 3xpb protein surface; visualized with GL mol viewer, DockingServer.

Thermodynamic parameters

The binding of drugs to biomolecules has been theorized to be influenced by various thermodynamic factors such as binding free energy, electrostatic interactions, total intermolecular energy, and contributions from Van der Waals (vdW) forces, hydrogen bonding, and desolvation effects [29]. To explore the role of these parameters in the interaction between thiophene and its derivatives with the 3pxb protein, a detailed analysis was conducted. The outcomes, as shown in **Table 2**, demonstrated notable variations in the energy levels of thiophene derivatives compared to niraparib. Additionally, the inhibition constant (Ki) for most of the thiophene derivatives (2-10, 12, 14, 15, 17, 19, 21-25) was found to be higher than that of niraparib. In contrast, derivatives 11, 13, 16, 18, and 20 exhibited Ki values very similar to that of niraparib. These results suggest that compounds 11, 13, 16, 18, and 20 may have the potential to inhibit BRCA-1, although further experimental validation is necessary.

Table 2. Thermodynamic parameters for thiophene-3pxb-protein complex formation

Compound	A	B	C	D	E	F
Niraparib	-3.97	1.23	-4.45	0.17	-4.28	566.74
1	-2.69	10.64	-2.69	-0.01	-2.69	262.81
2	-3.20	4.52	-3.30	-0.19	-3.50	361.44
3	-5.71	65.54	-5.70	-0.01	-5.71	507.69

4	-5.15	166.84	-6.00	0.05	-5.95	639.36
5	-4.89	259.58	-5.42	-0.36	-5.78	502.05
6	-3.12	5.17	-3.41	-0.01	-3.42	324.30
7	-3.02	6.15	-3.70	0.01	-3.69	394.77
8	-5.29	132.58	-5.20	-0.09	-5.29	366.08
9	-3.09	5.39	-3.10	0.01	-3.09	312.43
10	-4.46	540.66	-4.50	-0.97	-5.47	479.82
11	-4.00	1.17	-3.98	-0.77	-4.76	410.80
12	-4.44	560.34	-4.11	-1.15	-5.26	426.31
13	-3.92	1.33	-3.92	-1.17	-5.09	434.79
14	-2.87	7.87	-3.12	-0.05	-3.17	293.08
15	-5.00	216.89	-4.99	0.00	-5.00	507.79
16	-3.77	1.74	-4.01	-0.05	-4.06	368.70
17	-5.09	186.30	-5.09	0.00	-5.09	493.21
18	-4.07	1.04	-5.12	-0.03	-5.14	559.29
19	-5.01	211.98	-5.01	0.00	-5.01	485.12
20	-3.72	1.89	-3.69	-0.02	-3.72	383.12
21	-3.40	3.22	3.38	-0.02	-3.40	372.32
22	-2.67	11.10	-2.65	0.02	-2.67	276.73
23	-2.30	20.55	-4.32	0.10	-4.21	616.39
24	-4.16	888.00	-4.15	-0.01	-4.15	402.99
25	-5.48	96.79	-5.47	0.00	-5.48	497.96

A = Est: free energy of binding (kcal/mol), B = Est. inhibition constant, Ki (mM), C = vdW + Hbond + desolv energy (kcal/mol), D = electrostatic energy (kcal/mol), E = total Intermolec. energy (kcal/mol), and F = Interact. surface.

Pharmacokinetic assessment

Various approaches have been employed to assess pharmacokinetic parameters to evaluate the potential biological effects of different pharmaceutical compounds [30-33]. Therefore, this study aimed to analyze certain pharmacokinetic properties of thiophene analogs 11, 13, 16, 18, 20, and niraparib using the SwissADME tool (**Table 3**). The findings revealed notable variations in gastrointestinal absorption and metabolism, involving different cytochrome P450 enzymes, between thiophene analogs 11, 13, 16, 18, and 20 and the niraparib drug. These differences are likely linked to the unique chemical features and varying lipophilicity of each thiophene derivative.

Table 3. Theoretical analysis of some pharmacokinetic factors for thiophene analogs and niraparib drug

Parameter	Niraparib	11	13	16	18	20
GI absorption	High	High	High	High	Low	High
BBB permeant	Yes	Yes	Yes	Yes	No	Yes
P-GP substrate	Yes	No	No	No	No	No
CYP1A2 inhibitor	Yes	Yes	Yes	Yes	Yes	Yes
CYP2C19 inhibitor	No	Yes	Yes	Yes	Yes	Yes
CYP2C9 inhibitor	No	No	No	No	Yes	No
CYP2D6 inhibitor	Yes	Yes	No	No	No	No
CYP3A4 inhibitor	No	No	No	No	No	No
Consensus LogP$_{O/w}$	2.29	3.14	2.49	2.02	5.17	3.19

Toxicity evaluation

Previous studies have indicated that certain thiophene derivatives can induce toxicity to varying degrees, depending on the biological models used for assessment [34-37]. In this study, the potential toxicity of thiophene

analogs (11, 13, 16, 18, and 20) was evaluated using the GUSAR software [28]. The findings, as shown in **Table 4**, suggest that compound 18 might require significantly higher doses to achieve toxicity (LD50) through different administration routes, including intraperitoneal, intravenous, oral, and subcutaneous, compared to niraparib. Furthermore, thiophene analog 16 requires a higher oral dose to induce toxicity than niraparib. These observations imply that the toxicity levels of thiophene derivatives vary based on the dosage and route of administration for each compound.

Table 4. Theoretical analysis of toxicity for thiophene derivatives (11, 13, 16, 18, and 20) and niraparib drug using GUSAR software.

Compound	IP LD50 (mg/kg)	IV LD50 (mg/kg)	Oral LD50 (mg/kg)	SC LD50 (mg/kg)
Niraparib	423.10	104.50	366.00	158.60
11	90.10	31.09	190.60	150.50
13	189.80	75.37	1154.00	374.60
16	216.20	115.80	868.40	181.00
18	586.60	285.20	465.80	307.50
20	227.60	63.58	1232.00	416.20

IP = intraperitoneal route of administration, IV = intravenous route of administration, Oral = oral route of administration, and SC = subcutaneous route of administration

Conclusion

This research explored the interaction between thiophene derivatives and the 3pxb protein surface. The findings suggest that compounds 11, 13, 16, 18, and 20 might interact with various amino acid residues on the 3pxb protein, positioning them as potential inhibitors of the BRCA-1 gene. Such inhibition may translate into reduced breast cancer cell proliferation, indicating that these thiophene derivatives could hold promise as therapeutic agents for breast cancer treatment.

References

1. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698
2. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409-36. doi:10.3322/caac.21731
3. Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/Black people 2022. CA Cancer J Clin. 2022;72(3):202-29. doi:10.3322/caac.21718
4. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151-64.
5. Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105-17. doi:10.1016/S0140-6736(22)02420-5

6. Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, et al. VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up. Ann Oncol. 2022;33(9):986-7. doi:10.1016/j.annonc.2022.06.009

7. Royce M, Osgood CL, Amatya AK, Fiero MH, Chang CJG, Ricks TK, et al. FDA approval summary: margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer. Clin Cancer Res. 2022;28(8):1487-92. doi:10.1158/1078-0432.CCR-21-3247

8. Yuan Y, Liu X, Cai Y, Li W. Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis. Syst Rev. 2022;11(1):264.

9. Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer. Clin Cancer Res. 2022;28(7):1258-67. doi:10.1158/1078-0432.CCR-21-3418

10. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321-9. doi:10.1016/j.annonc.2021.12.005

11. Moreau-Bachelard C, Robert M, Gourmelon C, Bourbouloux E, Patsouris A, Frenel JS, et al. Evaluating everolimus for the treatment of breast cancer. Expert Opin Pharmacother. 2023;24(10):1105-11. doi:10.1080/14656566.2023.2214677

12. Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley L, et al. Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer. Clin Cancer Res. 2022;28(8):1493-9. doi:10.1158/1078-0432.CCR-21-3045

13. Howell S, Casbard A, Carucci M, Ingarfield K, Butler R, Morgan S, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomized, phase 2 trial. Lancet Oncol. 2022;23(7):851-64. doi:10.1016/S1470-2045(22)00284-4

14. Geyer C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250-68. doi:10.1016/j.annonc. 2022.09.159

15. Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: an overview of drug classes and outcomes. Biochem Pharmacol. 2022;204(3):115209. doi:10.1016/j.bcp.2022.115209

16. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, et al. Discovery of 2-{4-[(3 S)-piperidin-3-yl] phenyl}-2 H-indazole-7-carboxamide (MK-4827): a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem. 2009;52(22):7170-85.

17. Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S. Poly (ADP-ribose) polymerase inhibition in patients with breast cancer and BRCA 1 and 2 mutations. Drugs. 2020;80(2):131-46.

18. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114-21. doi:10.3343/alm.2020.40.2.114

19. Jeffy BD, Schultz EU, Selmin O, Gudas JM, Bowden GT, Romagnolo D. Inhibition of BRCA-1 expression by benzo [a] pyrene and its diol epoxide. Mol Carcinog. 1999;26(2):100-18.

20. Chen X, Huan X, Liu Q, Wang Y, He Q, Tan C, et al. Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose) polymerase (PARP) inhibitors. Eur J Med Chem. 2018;145:389-403. doi:10.1016/j.ejmech.2018.01.018

21. Al-Owaidi MF, Mahdi MF. Synthesis and anti-breast cancer activity evaluation of the designed chlorobenzothiophene derivatives: promising estrogen receptor alpha inhibitors. Egypt J Chem. 2023;66(10):431-41. doi:10.21608/EJCHEM.2023.153114.6633

22. Gomha SM, Riyadh SM, Huwaimel B, Zayed MEM, Abdellattif MH. Synthesis, molecular docking study, and cytotoxic activity against MCF cells of new thiazole-thiophene scaffolds. Molecules. 2022;27(14):4639. doi:10.3390/molecules27144639

23. Ahmed SA, Kamel MS, Aboelez MO, Ma X, Al-Karmalawy AA, Mousa SA, et al. Thieno [2, 3-b] thiophene derivatives as potential EGFRWT and EGFRT790M inhibitors with antioxidant activities: microwave-

assisted synthesis and quantitative in vitro and in silico studies. ACS Omega. 2022;7(49):45535-44. doi:10.1021/acsomega.2c06219

24. Son Y, Kim J, Kim Y, Chi SG, Kim T, Yu J. Discovery of dioxo-benzo [b] thiophene derivatives as potent YAP-TEAD interaction inhibitors for treating breast cancer. Bioorg Chem. 2023;131(6):106274. doi:10.1016/j.bioorg.2022.106274

25. Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, et al. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss. Bioorg Med Chem. 2023;78:117133. doi:10.1016/j.bmc.2022.117133

26. Coquelle N, Green R, Glover JN. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. Biochemistry. 2011;50(21):4579-89. doi:10.1021/bi2003795

27. Figueroa-Valverde L, Diaz-Cedillo F, Nexticapa MR, Alvarez-Ramirez M, López-Ramos M, Melgarejo-Guttierrez M, et al. Biochemical interaction of twenty steroid derivatives with ribosomal protein kinase 4 S6 (RSK-4) surface using a theoretical model. Braz J Sci. 2024;3(2):66-81. doi:10.14295/bjs.v3i2.482

28. Lauro F, Francisco D, Ricardo G, Heidari A, Marcela Maria L. Design and synthesis of two Strychnidin-oxiran-naphthalenol derivatives and their theoretical evaluation as noradrenaline and serotonin reuptake inhibitors. Vietnam J Chem. 2022;60(2):245-56. doi:10.1002/ vjch.202100128

29. Figueroa-Valverde L, Díaz-Cedillo F, Rosas-Nexticapa M, Alvarez-Ramirez M, Mateu-Armad M, López-Ramos M. Interaction of some amino-nitrile derivatives with vascular endothelial growth factor receptor 1 (VEGFR1) using a theoretical model. Drug Res. 2023;73(06):355-64. doi:10.1055/a-2062-3571

30. Vishal K, Singla C, Sharma A, Dhiman A. Prediction of environmental toxicity of active chemical constituents of ipomoea carnea through GUSAR software. Turk J Comput Math Educ. 2020;11(2):735-40.

31. Levitt DG. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol. 2002;2(1):5. doi:10.1186/1472-6904-2-5

32. Ishaku SG, Bakare-Odunola MT, Musa A, Yakasai IA, Garba M, Adzu B. Effect of dihydro-artemisinin on the pharmacokinetics of gliclazide in diabetic subjects. Int J Biol Chem. 2020;14(6):2267-76. doi:10.4314/ijbcs.v14i6.27

33. Sicak Y. Design and antiproliferative and antioxidant activities of furan-based thiosemicarbazides and 1, 2, 4-triazoles: their structure-activity relationship and SwissADME predictions. Med Chem Res. 2021;30(8):1557-68.

34. Mohareb RM, Ibrahim RA. Design, cytotoxicity and toxicity of new thiophene and thieno [2, 3-b] pyridine derivatives. Med Chem Res. 2017;26(3):587-602.

35. Lisboa T, Silva D, Duarte S, Ferreira R, Andrade C, Lopes AL, et al. Toxicity and antitumor activity of a thiophene-acridine hybrid. Molecules. 2019;25(1):64. doi:10.3390/molecules25010064

36. Jaladanki C, Taxak N, Varikoti R, Bharatam P. Toxicity originating from thiophene-containing drugs: exploring the mechanism using quantum chemical methods. Chem Res Toxicol. 2015;28(12):2364-76. doi:10.1021/acs.chemrestox.5b00364

37. Mosier PD, Jurs PC, Custer LL, Durham SK, Pearl GM. Predicting the genotoxicity of thiophene derivatives from molecular structure. Chem Res Toxicol. 2003;16(6):721-32. doi:10.1021/tx020104